Based on these findings, dual inhibition of sclerostin and DKK1 by administration of a bispecific antibody increased bone formation and improved fracture healing in rodents [52], suggesting that a simultaneous inhibition of sclerostin and DKK1 may result in superior results in osteoporosis treatment. Here, SOST is linked to osteoporosis.